Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Roche

It's Official: Novartis SMA Gene Therapy Zolgensma Is World's Most Expensive Drug

The total cost of Zolgensma is more than $2m – in line with estimates – or $425,000 annually for five years if payers choose an annuity-like payment plan. Novartis is also negotiating value-based reimbursement agreements for infants treated with the one-time infusion.

Approvals Gene Therapy

In Immunology, J&J Makes A Big Move On Biologic Combinations

The company has initiated a Phase II study of Tremfya and Simponi in combination for the treatment of ulcerative colitis, J&J's first human study of two targeted immunology drugs together. 
Biologics Clinical Trials

NHS England Offers ‘Improved’ Orkambi Deal, But Vertex Lukewarm

The NHS in England says it has made a “revised and improved” offer to Vertex to make Orkambi available, but the company is not impressed and says its attitude to the negotiations has been mischaracterized.
Health Technology Assessment Pricing Debate

Cipla Claims Pricing Advantage For Albuterol In US

Cipla, which expects to enter the US albuterol inhalation market later this year, believes that it has the cost competitiveness to price “significantly lower” than competition and take a “fair share” of a market that recently saw the arrival of authorized generics.

Commercial Strategy
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register